1. Home
  2. CRI vs CAPR Comparison

CRI vs CAPR Comparison

Compare CRI & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carter's Inc.

CRI

Carter's Inc.

HOLD

Current Price

$36.13

Market Cap

1.2B

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$24.21

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRI
CAPR
Founded
1865
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2003
N/A

Fundamental Metrics

Financial Performance
Metric
CRI
CAPR
Price
$36.13
$24.21
Analyst Decision
Sell
Strong Buy
Analyst Count
5
8
Target Price
$29.40
$41.38
AVG Volume (30 Days)
1.1M
1.3M
Earning Date
02-24-2026
11-10-2025
Dividend Yield
2.76%
N/A
EPS Growth
N/A
N/A
EPS
2.45
N/A
Revenue
$2,832,687,000.00
$11,130,509.00
Revenue This Year
$2.18
N/A
Revenue Next Year
N/A
$16,329.74
P/E Ratio
$14.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.38
$4.30
52 Week High
$55.71
$40.37

Technical Indicators

Market Signals
Indicator
CRI
CAPR
Relative Strength Index (RSI) 63.34 50.10
Support Level $34.00 $23.53
Resistance Level $37.24 $25.44
Average True Range (ATR) 1.53 1.66
MACD 0.28 -1.01
Stochastic Oscillator 66.67 14.35

Price Performance

Historical Comparison
CRI
CAPR

About CRI Carter's Inc.

Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: